A detailed history of Bridgeway Capital Management, LLC transactions in X Biotech Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 147,592 shares of XBIT stock, worth $982,962. This represents 0.03% of its overall portfolio holdings.

Number of Shares
147,592
Previous 154,178 4.27%
Holding current value
$982,962
Previous $792,000 43.94%
% of portfolio
0.03%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.55 - $7.95 $36,552 - $52,358
-6,586 Reduced 4.27%
147,592 $1.14 Million
Q2 2024

Aug 14, 2024

BUY
$4.54 - $9.89 $22,064 - $48,065
4,860 Added 3.25%
154,178 $792,000
Q1 2024

May 15, 2024

BUY
$4.03 - $8.13 $19,041 - $38,414
4,725 Added 3.27%
149,318 $1.21 Million
Q4 2023

Feb 14, 2024

BUY
$3.56 - $4.65 $19,053 - $24,886
5,352 Added 3.84%
144,593 $578,000
Q3 2023

Nov 14, 2023

BUY
$4.02 - $5.81 $50,511 - $73,002
12,565 Added 9.92%
139,241 $573,000
Q2 2023

Aug 14, 2023

BUY
$3.06 - $6.38 $37,748 - $78,703
12,336 Added 10.79%
126,676 $752,000
Q1 2023

May 15, 2023

SELL
$3.22 - $4.72 $29,173 - $42,763
-9,060 Reduced 7.34%
114,340 $394,000
Q4 2022

Feb 14, 2023

SELL
$3.03 - $3.79 $29,087 - $36,384
-9,600 Reduced 7.22%
123,400 $433,000
Q3 2022

Nov 14, 2022

BUY
$3.58 - $5.88 $366,950 - $602,700
102,500 Added 336.07%
133,000 $481,000
Q2 2022

Aug 15, 2022

BUY
$5.13 - $9.2 $156,465 - $280,600
30,500 New
30,500 $172,000
Q3 2020

Nov 16, 2020

SELL
$13.97 - $21.16 $311,531 - $471,868
-22,300 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$10.39 - $16.07 $231,697 - $358,361
22,300 New
22,300 $306,000

Others Institutions Holding XBIT

About XBiotech Inc.


  • Ticker XBIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,439,300
  • Market Cap $203M
  • Description
  • XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...
More about XBIT
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.